Portal de Periódicos da CAPES

Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India

2019; American Society of Clinical Oncology; Issue: 5 Linguagem: Inglês

10.1200/jgo.18.00184

2378-9506

Ajay Gogia, S. V. S. Deo, Dayanand Sharma, R.K. Phulia, Sanjay Thulkar, Prabhat Singh Malik, Sandeep Mathur,

Cancer Treatment and Pharmacology

Biomarker-estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/ neu) -discordance plays an essential role in the management and prognosis of patients with metastatic breast cancer. Rates of discordance have been previously reported around 12% to 35%, 30% to 50%, and 5% to 15%, respectively, in Western literature. Data are sparse regarding the same from developing countries, such as India.